APPLICANTS: U.S.S.N.:

Chagnaud et al. 09/331,980

-- For "Aminoguanidine": (Figure 28) anti-NO-Tyr is the highest response; the OD are between 1.5 and 2 (between the 2nd and 5th weeks). The anti-N02-Tyr response is as large; note an increase in signals between the 1st and 2nd weeks. They stabilize until the 3rd week, then increase slightly toward the 4th week.--

Please insert a "-" before the first letter of the underlined subheading on the following pages/lines: page, 10, line 5; page 13, line 4; and page 13, line 21.

Please delete the "." in front of the first letter of the subheading on the following pages/lines and replace each occurrence with a "-": page 22, line 14; page 22, line 32; page 23, line 7; page 23, line 10; page 24, line 21; page 25, line 11; page 25, line 34; page 26, line 9; page 26, line 15; page 29, line 32; page 30, line 4; page 31, line 5; page 33, line 18; page 33, line 27; page 34, line 8; page 41, line 8; page 46, line 18; page 46, line 16; page 46, line 18; page 46, line 27; page 46, line 29; page 46, line 32; page 53, line 12; page 53, line 18; page 53, line 31; page 54, line 3; page 54, line 14; page 54, line 21; page 54, line 26; page 55, line 22; page 55, line 30; page 56, line 3; page 56, line 23; page 56, line 28; page 56, line 30; page 58, line 13; page 58, line 15; page 58, line 19; page 58, line 21; page 59, line 12; page 59, line 14; page 59, line 16; page 59, line 17; page 59, line 28, page 59, line 29; page 59, line 30; page 59, line 32; page 60, line 15; and page 62, line 5.

In the Claims:

On pg. 89, line 2, kindly insert -- We claim--.

Kindly amend claims 1-5, 11 and 14 as follows:

1. (Amended) A purified antibody, wherein the antibody binds specifically to a nitrosylated protein.

APPLICANTS: U.S.S.N.:

Chagnaud *et al.* 09/331,980

- 2. (Amended) The antibody of Claim 1, wherein the nitrosylated protein is a transporter of NO.
- C1 cmx
 - 3. (Twice amended) The antibody of Claim 1, wherein the antibody binds specifically to a nitrosylated albumin.
 - 4. (Twice amended) The antibody of Claim 1, wherein the antibody is a polyclonal antibody.
 - 5. (Twice amended) The antibody of Claim 1, wherein the antibody is a monoclonal antibody.
- (v
- 11. (Twice amended) A pharmaceutical composition, comprising:
 - (a) a purified antibody that binds specifically to a nitrosylated protein; and
 - (b) a pharmaceutically acceptable excipient.
- 14. (Twice amended) A kit for *in vitro* detection of nitrosylated proteins in a biological specimen, comprising:
 - (a) a purified antibody that binds specifically to a nitrosylated protein, and
- (b) reagents to produce a medium favorable for an immunological reaction between said purified antibody and any nitrosylated proteins that may be present in a biological specimen.